Boston Scientific: 15%
Boston Scientific has had a busy 1st quarter, investing $45 million in robotic platform maker Corindus Vascular Robotics, putting up $435 million for replacement heart valve developer Symetis and reportedly eyeing a buyout of mitral valve maker Neovasc.
The Marlborough, Mass.–based company has seen share value grow roughly 15% so far in the year, beginning the year at $21.63 and hitting $24.87 on March 31.
The solid share performance comes despite stock values dipping nearly 5% in February after the company announced a voluntary recall of its Lotus transcatheter aortic valve replacement over issues with its locking mechanism.
The company said it reportedly found a “fix” for issues with its Lotus Edge heart valve in January, and is hopeful to file for premarket approval with the FDA some time in May.